|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.072 AUD | -6.49% |
|
-6.49% | -24.21% |
| 03/07 | Island Pharmaceuticals Acquiring Clinical-Stage Antiviral Molecule | MT |
| 08/05 | Island Pharmaceuticals Reallocates Grant Funding to Dengue Fever Trial; Shares Rally 13% | MT |
Island Pharmaceuticals Limited reported earnings results for the half year ended December 31, 2023. For the half year, the company reported revenue was AUD 0.96282 million compared to AUD 0.004559 million a year ago. Net loss was AUD 1.16 million compared to AUD 1.61 million a year ago.
Basic loss per share from continuing operations was AUD 0.0142 compared to AUD 0.0198 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -24.21% | 59.7L | |
| +15.58% | 12TCr | |
| +16.60% | 11TCr | |
| +17.55% | 2.62TCr | |
| -24.33% | 1.9TCr | |
| -19.14% | 1.57TCr | |
| -17.95% | 1.52TCr | |
| -46.81% | 1.47TCr | |
| +58.78% | 1.46TCr | |
| +4.91% | 1.38TCr |
ISLAND PHARMACEUTICALS LIMITED 
